EGRX — Eagle Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $12.99m
- $67.83m
- $316.61m
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq
Brief: Eagle Pharmaceuticals Gets Nasdaq Deficiency Notice On Requirement To Timely File Annual Report On Form 10-K
Brief: Eagle Pharmaceuticals Inc - Brian Cahill Resigned From His Position As CFO Effective Immediately
Brief: Eagle Pharmaceuticals Approves Plan Designed To Improve Operational Efficiencies And Realign Sales & Marketing Expenditures
Brief: Eagle Pharmaceuticals Enters Into Limited Waiver And First Amendment To Third Amended And Restated Credit Agreement
Brief: Eagle Pharmaceuticals Announces Financial Statements For Quarter Ended June 30, 2023 To No Longer Be Relied Upon
Brief: Eagle Pharmaceuticals Says Co Expects To Revise Its Previously Disclosed 2023 Full Year Guidance Downward
Eagle Pharmaceuticals Inc expected to post earnings of $1.09 a share - Earnings Preview
Brief: Tailormed Partners With Eagle Pharmaceuticals To Streamline Patient Financial Assistance Enrollment
Brief: Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS from CMS
Brief: Eagle Pharmaceuticals Reiterates 2023 Adjusted Non-GAAP EBITDA And Adjusted Non-GAAP E¹ Guidance
Brief: Eagle Pharmaceuticals Outlook FY Adjusted EBITDA USD 78-84 Million
Eagle Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Eagle Pharmaceuticals Q2 Revenue USD 64.6 Million
Eagle Pharmaceuticals Inc expected to post earnings of $1.05 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baxter International, Johnson & Johnson, Ford Motor